Search
Policy on double awarding
We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.
Read morePolicy on double awarding
We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.
Read morePolicy on double awarding
We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.
Read morePolicy on double awarding
We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.
Read moreHighlights of Past EHA (HOPE) Asia 2023
EHA joined forces with the Indian Society of Hematology & Blood Transfusion (ISHBT) to organize the 5th edition of the Highlights of Past EHA (HOPE) Asia 2023 meeting.
Read moreApplication forms
The deadline for the EHA Corporate Sponsor application is September 6, 2024, at 13:00 (CEST). Interested in becoming an EHA sponsor? Below you will find all the application forms for all the available EHA Sponsor Programs.
Read morePress release: 18th Congress of the European Hematology Association in Stockholm, Sweden June 13-16-2013
The EHA-theme of the year, from June 2013 to June 2014, is dedicated to “Age and Aging in blood disorders”.
Read moreRegistration
Register here
The registration fee for the ESH-EBMT-EHA-IPIG 3rd Translational Research Conference: Bone Marrow Failure and Leukaemia Predisposition Syndromes is:
– 600€ for fully trained
– 300€ for in-training *
– 300€ Allied Health Professionals
– 600€ for Corporate
*A proof will be requested to confirm your status.…
Other Useful Resources
Latest EMA publications on COVID-19 vaccines
COVID-19 Vaccine Janssen: update on safety issues
First COVID-19 vaccine approved for children aged 12 to 15 in EU
Insufficient data on use of inhaled corticosteroids to treat COVID-19
EMA issues advice on use of sotrovimab (VIR-7831) for…
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- »